Pediatric Solid Malignancies: Neuroblastoma and Wilms' Tumor

Surgical Clinics of North America

Volumn 86, Issue 2, 2006, Pages 469-487

  Kim, Sunghoon ^a   Chung, Dai H ^b  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FERRITIN; HERMES ANTIGEN; IFOSFAMIDE; IRON BINDING PROTEIN; LACTATE DEHYDROGENASE; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN; NERVE GROWTH FACTOR; NEURON SPECIFIC ENOLASE; TECHNETIUM 99M; TYROSINE KINASE RECEPTOR; VINCRISTINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CYTOGENETICS; DEHYDRATION; DRUG MECHANISM; ECHOGRAPHY; FERRITIN BLOOD LEVEL; FEVER; HISTOPATHOLOGY; HUMAN; HYPOKALEMIA; IMAGING; LACTATE DEHYDROGENASE BLOOD LEVEL; MALAISE; MYOCLONUS; NEPHROBLASTOMA; NEUROBLASTOMA; ONCOGENE C MYB; PARANEOPLASTIC SYNDROME; PATHOLOGY; PEDIATRICS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; REVIEW; SCREENING; SOLID TUMOR; STATISTICAL ANALYSIS; SURGICAL TECHNIQUE; SYMPTOM; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; WHOLE BODY RADIATION;

CHILD; COMBINED MODALITY THERAPY; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; NEUROBLASTOMA; UNITED STATES; WILMS TUMOR;

EID: 33645868964     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2005.12.008     Document Type: Review

References (85)

1. Gurney J.G., Severson R.K., Davis S., et al. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 75 (1995) 2186-2195
2. Hicks M.J., and Mackay B. Comparison of ultrastructural features among neuroblastic tumors: maturation from neuroblastoma to ganglioneuroma. Ultrastruct Pathol 19 (1995) 311-322
3. Peuchmaur M., d'Amore E.S., Joshi V.V., et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 98 (2003) 2274-2281
4. Chatten J., Shimada H., Sather H.N., et al. Prognostic value of histopathology in advanced neuroblastoma: a report from the Childrens Cancer Study Group. Hum Pathol 19 (1988) 1187-1198
5. Shimada H. Tumors of the neuroblastoma group. Pathology (Phila) 2 (1993) 43-59
6. Shimada H., Ambros I.M., Dehner L.P., et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86 (1999) 364-372
7. Brodeur G.M., Green A.A., Hayes F.A., et al. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 41 (1981) 4678-4686
8. Gilbert F., Balaban G., Moorhead P., et al. Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines. Cancer Genet Cytogenet 7 (1982) 33-42
9. Brodeur G.M., Fong C.T., Morita M., et al. Molecular analysis and clinical significance of N-myc amplification and chromosome 1p monosomy in human neuroblastomas. Prog Clin Biol Res 271 (1988) 3-15
10. Srivatsan E.S., Ying K.L., and Seeger R.C. Deletion of chromosome 11 and of 14q sequences in neuroblastoma. Genes Chromosomes Cancer 7 (1993) 32-37
11. Attiyeh E.F., London W.B., Mosse Y.P., et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353 (2005) 2243-2253
12. Gilbert F., Feder M., Balaban G., et al. Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res 44 (1984) 5444-5449
13. Look A.T., Hayes F.A., Nitschke R., et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311 (1984) 231-235
14. Berthold F., Engelhardt-Fahrner U., Schneider A., et al. Age dependence and prognostic impact of neuron specific enolase (NSE) in children with neuroblastoma. In Vivo 5 (1991) 245-247
15. Silber J.H., Evans A.E., and Fridman M. Models to predict outcome from childhood neuroblastoma: the role of serum ferritin and tumor histology. Cancer Res 51 (1991) 1426-1433
16. Joshi V.V., Cantor A.B., Brodeur G.M., et al. Correlation between morphologic and other prognostic markers of neuroblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group. Cancer 71 (1993) 3173-3181
17. Woods W.G. The use and significance of biologic markers in the evaluation and staging of a child with cancer. Cancer 58 (1986) 442-448
18. Brodeur G.M., Seeger R.C., Schwab M., et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224 (1984) 1121-1124
19. Look A.T., Hayes F.A., Shuster J.J., et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 9 (1991) 581-591
20. Bordow S.B., Haber M., Madafiglio J., et al. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 54 (1994) 5036-5040
21. Norris M.D., Bordow S.B., Marshall G.M., et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334 (1996) 231-238
22. Weiss W.A., Aldape K., Mohapatra G., et al. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16 (1997) 2985-2995
23. Negroni A., Scarpa S., Romeo A., et al. Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line. Cell Growth Differ 2 (1991) 511-518
24. Whitesell L., Rosolen A., and Neckers L.M. Episome-generated N-myc antisense RNA restricts the differentiation potential of primitive neuroectodermal cell lines. Mol Cell Biol 11 (1991) 1360-1371
25. Esteban F., Bravo J.J., Gonzalez-Moles M.A., et al. Adhesion molecule CD44 as a prognostic factor in laryngeal cancer. Anticancer Res 25 (2005) 1115-1121
26. Kashyap M.K., Kumar A., Emelianenko N., et al. Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers 10 (2005) 258-294
27. Comito M.A., Savell V.H., and Cohen M.B. CD44 expression in neuroblastoma and related tumors. J Pediatr Hematol Oncol 19 (1997) 292-296
28. Combaret V., Gross N., Lasset C., et al. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma. Eur J Cancer 33 (1997) 2101-2105
29. Kramer K., Cheung N.K., Gerald W.L., et al. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma. Eur J Cancer 33 (1997) 2098-2100
30. Wei J.S., Greer B.T., Westermann F., et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 64 (2004) 6883-6891
31. Nakagawara A., Arima-Nakagawara M., Scavarda N.J., et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328 (1993) 847-854
32. Matsushima H., and Bogenmann E. Expression of trkA cDNA in neuroblastomas mediates differentiation in vitro and in vivo. Mol Cell Biol 13 (1993) 7447-7456
33. Hiyama E., Yokoyama T., Ichikawa T., et al. Poor outcome in patients with advanced stage neuroblastoma and coincident opsomyoclonus syndrome. Cancer 74 (1994) 1821-1826
34. El Shafie M., Samuel D., Klippel C.H., et al. Intractable diarrhea in children with VIP-secreting ganglioneuroblastomas. J Pediatr Surg 18 (1983) 34-36
35. LaBrosse E.H., Com-Nougue C., Zucker J.M., et al. Urinary excretion of 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid by 288 patients with neuroblastoma and related neural crest tumors. Cancer Res 40 6 (1980) 1995-2001
36. Laug W.E., Siegel S.E., Shaw K.N., et al. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 62 (1978) 77-83
37. Tajiri T., Suita S., Sera Y., et al. Clinical and biologic characteristics for recurring neuroblastoma at mass screening cases in Japan. Cancer 92 (2001) 349-353
38. Andrich M.P., Shalaby-Rana E., Movassaghi N., et al. The role of 131 iodine-metaiodobenzylguanidine scanning in the correlative imaging of patients with neuroblastoma. Pediatrics 97 (1996) 246-250
39. Gordon I., Peters A.M., Gutman A., et al. Skeletal assessment in neuroblastoma-the pitfalls of iodine-123-MIBG scans. J Nucl Med 31 (1990) 129-134
40. Brodeur G.M., Pritchard J., Berthold F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11 (1993) 1466-1477
41. Matthay K.K., O'Leary M.C., Ramsay N.K., et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer 31A (1995) 572-575
42. De Kraker J., Hoefnagel C.A., Caron H., et al. First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer 31A (1995) 600-602
43. Kang T.I., Brophy P., Hickeson M., et al. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. J Pediatr Hematol Oncol 25 (2003) 769-773
44. Mairs R.J., Fullerton N.E., Cosimo E., et al. Gene manipulation to enhance MIBG-targeted radionuclide therapy. Nucl Med Biol 32 (2005) 749-753
45. Garaventa A., Gambini C., Villavecchia G., et al. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer 97 (2003) 1332-1338
46. van Santen H.M., de Kraker J., van Eck B.L., et al. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer 94 (2002) 2081-2089
47. von Allmen D., Grupp S., Diller L., et al. Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant. J Pediatr Surg 40 (2005) 936-941
48. Bonadio J.F., Storer B., Norkool P., et al. Anaplastic Wilms' tumor: clinical and pathologic studies. J Clin Oncol 3 (1985) 513-520
49. Beckwith J.B. Wilms' tumor and other renal tumors of childhood: a selective review from the National Wilms' Tumor Study Pathology Center. Hum Pathol 14 (1983) 481-492
50. Beckwith J.B. Precursor lesions of Wilms tumor: clinical and biological implications. Med Pediatr Oncol 21 (1993) 158-168
51. Beckwith J.B., Kiviat N.B., and Bonadio J.F. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. Pediatr Pathol 10 (1990) 1-36
52. Knudson Jr. A.G., and Strong L.C. Mutation and cancer: a model for Wilms' tumor of the kidney. J Natl Cancer Inst 48 (1972) 313-324
53. Miller R.W., Fraumeni Jr. J.F., and Manning M.D. Association of Wilms's tumor with aniridia, hemihypertrophy and other congenital malformations. N Engl J Med 270 (1964) 922-927
54. Riccardi V.M., Sujansky E., Smith A.C., et al. Chromosomal imbalance in the aniridia-Wilms' tumor association: 11p interstitial deletion. Pediatrics 61 (1978) 604-610
55. Miles C., Elgar G., Coles E., et al. Complete sequencing of the Fugu WAGR region from WT1 to PAX6: dramatic compaction and conservation of synteny with human chromosome 11p13. Proc Natl Acad Sci U S A 95 (1998) 13068-13072
56. Roberts S.G. Transcriptional regulation by WT1 in development. Curr Opin Genet Dev 15 (2005) 542-547
57. Dharnidharka V.R., Ruteshouser E.C., Rosen S., et al. Pulmonary dysplasia, Denys-Drash syndrome and Wilms tumor 1 gene mutation in twins. Pediatr Nephrol 16 (2001) 227-231
58. Coppes M.J., and Egeler R.M. Genetics of Wilms' tumor. Semin Urol Oncol 17 (1999) 2-10
59. Steenman M., Westerveld A., and Mannens M. Genetics of Beckwith-Wiedemann syndrome-associated tumors: common genetic pathways. Genes Chromosomes Cancer 28 (2000) 1-13
60. Malkin D., Sexsmith E., Yeger H., et al. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor. Cancer Res 54 (1994) 2077-2079
61. Grundy P.E., Telzerow P.E., Breslow N., et al. Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome. Cancer Res 54 (1994) 2331-2333
62. Owens C.M., Veys P.A., Pritchard J., et al. Role of chest computed tomography at diagnosis in the management of Wilms' tumor: a study by the United Kingdom Children's Cancer Study Group. J Clin Oncol 20 (2002) 2768-2773
63. Wilimas J.A., Kaste S.C., Kauffman W.M., et al. Use of chest computed tomography in the staging of pediatric Wilms' tumor: interobserver variability and prognostic significance. J Clin Oncol 15 (1997) 2631-2635
64. Ritchey M.L., Green D.M., Breslow N.B., et al. Accuracy of current imaging modalities in the diagnosis of synchronous bilateral Wilms' tumor. A report from the National Wilms Tumor Study Group. Cancer 75 (1995) 600-604
65. Ritchey M.L., Shamberger R.C., Hamilton T., et al. Fate of bilateral renal lesions missed on preoperative imaging: a report from the National Wilms Tumor Study Group. J Urol 174 4 (2005) 1519-1521
66. Shamberger R.C., Guthrie K.A., Ritchey M.L., et al. Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4. Ann Surg 229 (1999) 292-297
67. Ritchey M.L., Green D.M., Thomas P.R., et al. Renal failure in Wilms' tumor patients: a report from the National Wilms' Tumor Study Group. Med Pediatr Oncol 26 (1996) 75-80
68. Haecker F.M., von Schweinitz D., Harms D., et al. Partial nephrectomy for unilateral Wilms tumor: results of study SIOP 93-01/GPOH. J Urol 170 (2003) 939-942
69. Moorman-Voestermans C.G., Aronson D.C., Staalman C.R., et al. Is partial nephrectomy appropriate treatment for unilateral Wilms' tumor?. J Pediatr Surg 33 (1998) 165-170
70. Shamberger R.C., Ritchey M.L., Haase G.M., et al. Intravascular extension of Wilms tumor. Ann Surg 234 (2001) 116-121
71. Szavay P., Luithle T., Semler O., et al. Surgery of cavoatrial tumor thrombus in nephroblastoma: a report of the SIOP/GPOH study. Pediatr Blood Cancer 43 (2004) 40-45
72. Montgomery B.T., Kelalis P.P., Blute M.L., et al. Extended followup of bilateral Wilms tumor: results of the National Wilms Tumor Study. J Urol 146 (1991) 514-518
73. Horwitz J.R., Ritchey M.L., Moksness J., et al. Renal salvage procedures in patients with synchronous bilateral Wilms' tumors: a report from the National Wilms' Tumor Study Group. J Pediatr Surg 31 (1996) 1020-1025
74. D'Angio G.J., Breslow N., Beckwith J.B., et al. Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer 64 (1989) 349-360
75. Green D.M., Breslow N.E., Beckwith J.B., et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 16 (1998) 237-245
76. Green D.M., Breslow N.E., Beckwith J.B., et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 16 (1998) 3744-3751
77. Green D.M., Grigoriev Y.A., Nan B., et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol 19 (2001) 1926-1934
78. Pritchard-Jones K., Kelsey A., Vujanic G., et al. Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group. J Clin Oncol 21 (2003) 3269-3275
79. Thomas P.R., Tefft M., Compaan P.J., et al. Results of two radiation therapy randomizations in the third National Wilms' Tumor Study. Cancer 68 (1991) 1703-1707
80. Thomas P.R., Tefft M., Farewell V.T., et al. Abdominal relapses in irradiated second National Wilms' Tumor Study patients. J Clin Oncol 2 (1984) 1098-1101
81. Meisel J.A., Guthrie K.A., Breslow N.E., et al. Significance and management of computed tomography detected pulmonary nodules: a report from the National Wilms Tumor Study Group. Int J Radiat Oncol Biol Phys 44 (1999) 579-585
82. Greenberg M., Burnweit C., Filler R., et al. Preoperative chemotherapy for children with Wilms' tumor. J Pediatr Surg 26 (1991) 949-953
83. Zuppan C.W., Beckwith J.B., Weeks D.A., et al. The effect of preoperative therapy on the histologic features of Wilms' tumor. An analysis of cases from the Third National Wilms' Tumor Study. Cancer 68 (1991) 385-394
84. McLorie G.A., McKenna P.H., Greenberg M., et al. Reduction in tumor burden allowing partial nephrectomy following preoperative chemotherapy in biopsy proved Wilms tumor. J Urol 146 (1991) 509-513
85. Wilimas J.A., Magill L., Parham D.M., et al. Is renal salvage feasible in unilateral Wilms' tumor? Proposed computed tomographic criteria and their relation to surgicopathologic findings. Am J Pediatr Hematol Oncol 12 (1990) 164-167